Elaine R. Mardis
Immunology and Microbiology · The Ohio State University
Publications
1,712
Citations
343,511
Est. group size
~56
Recurring co-author estimate
Active years
40
Publishing since 1987
Elaine R. Mardis's research focuses on using genomic and molecular profiling technologies to understand cancer, including how tumors interact with the immune system. Her recent work involves identifying tumor neoantigens (mutated proteins that can be targeted by the immune system), designing personalized cancer vaccines, and studying blood cancers such as acute myeloid leukemia and brain tumors like glioblastoma. This work combines DNA/RNA sequencing, mass spectrometry, and single-cell analysis techniques to inform new cancer treatments.
Publication output has grown substantially over the last decade, with a sharp increase from roughly 27-67 papers per year before 2022 to over 200-500 papers in 2023-2024, suggesting rapidly expanding research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Table S10 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Figure S4 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S3 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S5 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S4 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S1 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S2 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S13 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S12 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S15 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Table S14 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Figure S2 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Figure S6 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Figure S7 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
2026
- Cancer Research×33
- Nature Communications×29
- Neuro-Oncology×24
- bioRxiv (Cold Spring Harbor Laboratory)×22
- Nature Genetics×19
- Elizabeth A.R. Garfinkle
Immunology and Microbiology · The Ohio State University
- Katherine E. Miller
Immunology and Microbiology · The Ohio State University
- Hakimeh Ebrahimi-Nik
Immunology and Microbiology · The Ohio State University
- Jay Overholser
Immunology and Microbiology · Indiana University
- Huijuan Song
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile